Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H21N3 |
Molecular Weight | 219.3259 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCCN(CCC)[C@]1([H])CC3=C(C2)NN=C3
InChI
InChIKey=FTSUPYGMFAPCFZ-ZWNOBZJWSA-N
InChI=1S/C13H21N3/c1-2-5-16-6-3-4-10-7-12-11(8-13(10)16)9-14-15-12/h9-10,13H,2-8H2,1H3,(H,14,15)/t10-,13-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8099277Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9806217 | https://www.ncbi.nlm.nih.gov/pubmed/2566488 | https://www.ncbi.nlm.nih.gov/pubmed/9926830 | https://www.ncbi.nlm.nih.gov/pubmed/28434589
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8099277
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9806217 | https://www.ncbi.nlm.nih.gov/pubmed/2566488 | https://www.ncbi.nlm.nih.gov/pubmed/9926830 | https://www.ncbi.nlm.nih.gov/pubmed/28434589
Quinpirole (LY 171,555) is a psychoactive drug and research chemical which acts as a selective D2 and D3 receptor agonist. Quinpirole is the most widely used D2 agonist in in vivo and in vitro studies. Specific quinpirole binding in rat brain was saturable, and dependent on temperature, membrane concentration, sodium concentration and guanine nucleotides. Saturation analysis revealed high affinity binding characteristics (KD = 2.3 nM) which were confirmed by association-dissociation kinetics. The regional distribution of [3H]quinpirole binding sites roughly paralleled the distribution of [3H]spiperone binding sites, with greatest densities present in the striatum, nucleus accumbens and olfactory tubercles. A variety of drugs, most notably monoamine oxidase inhibitors (MAOls), inhibit the binding of [3H]quinpirole, but not [3H]spiperone or [3H](-)N-n-Propylnorapomorphine, in rat striatal membranes by a mechanism that does not appear to involve the enzymatic activity of MAO. Clinically antidepressant MAOIs exhibited selectivity between sites labeled by [3H]quinpirole and [3H]spiperone as did a number of structurally related propargylamines and N-acylethylenediamine derivatives and other drugs such as debrisoquin and phenylbiguanide. Quinpirole has been shown to increase locomotion and sniffing behavior in mice and induces compulsive behavior symptomatic of obsessive compulsive disorder in rats.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24831693 |
9.8 nM [EC50] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24831693 |
19.0 nM [EC50] | ||
Target ID: CHEMBL2056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17154515 |
|||
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12617906 |
9.9 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Systemic hemodynamic and regional blood flow effects of LY141865, a selective dopamine receptor agonist. | 1984 Sep |
|
A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. | 1990 Nov |
|
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. | 1990 Sep 13 |
|
Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice. | 1991 |
|
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. | 1991 Apr 18 |
|
Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists. | 1991 Oct |
|
Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. | 1991 Oct |
|
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. | 1992 Apr 10 |
|
Effects of dopamine D1 and D2 receptor agonists and antagonists on seizures induced by chemoconvulsants in mice. | 1993 Apr-May |
|
Reserpine increases Fos activity in the rat basal ganglia via a quinpirole-sensitive mechanism. | 1994 May |
|
Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression. | 1994 Sep 26 |
|
K-channel blockers attenuate the presynaptic effects of the D2/D3 agonist quinpirole in monkeys. | 1995 Aug |
|
A functional test identifies dopamine agonists selective for D3 versus D2 receptors. | 1995 Jan 26 |
|
Lack of discrimination by agonists for D2 and D3 dopamine receptors. | 1995 Jul |
|
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). | 1995 Nov |
|
Roxindole, a potential antidepressant. I. Effect on the dopamine system. | 1996 |
|
Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. | 1996 Dec |
|
Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D1-like dopamine receptors. | 1996 Mar 1 |
|
Neuropsychopharmacological profile of remoxipride in comparison with clozapine. | 1997 Jan-Feb |
|
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. | 1997 Nov |
|
Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. | 1997 Oct 8 |
|
Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation. | 1998 |
|
Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. | 1998 May |
|
Acute nicotine pretreatment augments dopaminergic pulmonary vasodilation. | 1998 Oct |
|
Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. | 2002 Jul-Aug |
|
A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist. | 2002 Nov |
|
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. | 2002 Oct |
|
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. | 2003 Dec |
|
Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. | 2003 May |
|
Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. | 2003 Nov |
|
Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. | 2003 Oct |
|
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. | 2004 Aug |
|
Morphine state-dependent learning: sensitization and interactions with dopamine receptors. | 2004 Aug 23 |
|
Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway. | 2005 Apr |
|
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. | 2005 Feb 23 |
|
Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys. | 2005 Jun-Jul |
|
Locomotor activity and cocaine-seeking behavior during acquisition and reinstatement of operant self-administration behavior in rats. | 2005 May 28 |
|
Stimulation of D1-like or D2 dopamine receptors in the shell, but not the core, of the nucleus accumbens reinstates cocaine-seeking behaviour in the rat. | 2006 Jan |
|
The influence of central administration of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice. | 2006 Jan |
|
Control of the subthalamic innervation of substantia nigra pars reticulata by D1 and D2 dopamine receptors. | 2006 Mar |
|
Delayed L-DOPA-induced hyperalgesia. | 2006 Nov |
|
Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat. | 2006 Oct 13 |
|
Addiction-related alterations in D1 and D2 dopamine receptor behavioral responses following chronic cocaine self-administration. | 2007 Feb |
|
Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress. | 2007 Jan |
|
Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. | 2007 Jun 27 |
|
Maternal lead exposure produces long-term enhancement of dopaminergic reactivity in rat offspring. | 2007 Oct |
|
Effects of (-)-epigallocatechin gallate on the development of morphine-induced physical dependence. | 2007 Sep |
|
Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. | 2009 Jul |
|
Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats. | 2009 Sep-Oct |
|
Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist. | 2010 Sep 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28434589
0.5 mg/kg (two injections/week)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9806217
Adult, male, Sprague-Dawley rats (200-250g; Harlan Labs, Indianapolis, IN) were sacrificed by decapitation, the brains rapidly removed and dissected on ice. Striatal tissue was homogenized in 30 vol. ice-cold 0.32 M sucrose using a glass homogenizer and Teflon pestle. The crude nuclear fraction (P1), the pellet formed from centrifugation of the pellet at 1,000 x g for 10 mitt; the crude synaptosomal fraction (P2), the pellet formed by the centrifugation of the resulting supernatant at 20,000 x g for 30 min; Subfractionation of the crude synaptosomal fraction (P2) was performed by centrifugation of freshly prepared P2 fraction suspended in 0.32 M sucrose over a discontinuous gradient of 0.8 M and 1.2 M sucrose at 110,000 x g for 70 min. Three subfractions were collected. The myelin fraction (P2A) was collected at the 0.32 M/O.8 M sucrose interface; the synaptosomal fraction (P2B) at the 0.8 /1.2 M sucrose interface; and the mitochondrial fraction (P2C), the final pellet. All resulting fractions were resuspended in assay buffer and centrifuged at 100,000 x g for 30 min. The resulting pellets were used for receptor binding assays. The final fraction pellets were resuspended in assay buffer (50 mM Tris-HCl, 5 mM KCI, 2 mM MgCl2, and 2 mM CaCl2, pH 7.4 at 23°C) to yield a final protein concentration of 400 mkg/tube. Binding assays were performed in duplicate in disposable polystyrene tubes. Saturation analyses were performed in the major subcellular fractions to determine radioligand affinity. For saturation analyses, eight concentrations of [3H]quinpirole (43 Ci/mmol; NEN DuPont Research Products, Boston, MA) were used (0.1 to 30 nM). Because [3H]quinpirole exhibited similar affinity in the major subcellular fractions, single point analyses were used for subsequent experiments. For single point studies, the final concentration of [3H]quinpirole was ~2 nM Binding was initiated by the addition of resuspended subcellular fractionate. The total assay volume was 0.5 ml. Tubes were incubated at 23°C for 4 h
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL240773
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
D019257
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
C152128
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
100000080281
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
75401
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
20OP60125T
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
54562
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
QUINPIROLE
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
DTXSID9048229
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
5610
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
SUB10221MIG
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY | |||
|
80373-22-4
Created by
admin on Fri Dec 15 16:44:43 GMT 2023 , Edited by admin on Fri Dec 15 16:44:43 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)